Form 4: Jazz Pharmaceuticals Director Laura Hamill Reports Stock Transactions

Director Laura Hamill reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares and restricted stock units.

Summary

• On August 2, 2024, Director Laura Hamill acquired 3,731 ordinary shares of Jazz Pharmaceuticals at a price of $0.0.
• Following this acquisition, Ms. Hamill disposed of an unspecified amount of shares.
• After the reported transactions, Ms. Hamill beneficially owns 5,231 ordinary shares.
• Ms. Hamill was also granted restricted stock units under the company's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• These restricted stock units represent a contingent right to receive one ordinary share upon vesting, which is scheduled for July 25, 2025, subject to continuous service and other conditions.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions without indicating positive or negative implications for the company's performance.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders, incentivizing long-term value creation.

Future Outlook

The restricted stock units will vest on July 25, 2025, subject to continuous service and other conditions.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This allows investors to monitor the actions of directors and officers, which can provide insights into their confidence in the company's prospects.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding the transactions of a company director.

Key Dates